Jazz Pharmaceuticals (JAZZ) PT Raised to $176 at Morgan Stanley on Xyrem and Xywav

April 1, 2021 8:01 AM EDT
Get Alerts JAZZ Hot Sheet
Price: $165.99 -0.7%

Rating Summary:
    32 Buy, 3 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 6 | Down: 16 | New: 67
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Morgan Stanley analyst David Risinger raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $176.00 (from $162.00) on expected Xywav upside and the GW acquisition (expected to close in 2Q).

The analyst maintained an Overweight rating, stating "Jazz's conversion of Xyrem to Xywav is likely to be faster than anticipated, and the planned acquisition of GW Pharma (expected to close in 2Q) adds durable long-term growth to Jazz's portfolio. GW's key asset Epidiolex appears set for continued strong growth given its approval in three seizure types and potential for off-label use, and Epidiolex is unlikely to face generic competition until the mid-2030's."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Morgan Stanley, Definitive Agreement